Introduction
The importance of syncope as a clinical manifestation of acute pulmonary embolism (PE) was highlighted in 1880 by Dr Luzzatto 1 in his work on more than 160 patients with acute PE; he stated that 'loss of consciousness is the most important initial nervous manifestation, which is far from being uncommon'. According to cohort studies, the initial symptoms of acute PE include syncope in up to one-fourth of all cases. [2] [3] [4] Conversely, acute PE is diagnosed in one out of six patients admitted to the emergency room for a first episode of syncope without another identifiable source. 5 Several pathophysiological mechanisms have been proposed to explain syncope in PE; these include reduced cerebral perfusion secondary to a sudden drop in cardiac output, arrhythmias, or a vasovagal reflex. 5 Nevertheless, the aetiological link between acute PE and syncope, and particularly the possible prognostic impact of syncope as a presenting symptom on the early clinical course of a patient with acute PE, remain largely obscure. Current guidelines emphasize the role of risk stratification of acute PE in order to tailor initial management, including the need for admission and hospitalization, initial parenteral anticoagulation, haemodynamic monitoring, and occasionally reperfusion treatment. 6 Although a number of studies suggested that syncope may be associated with a higher risk of complications and death in the acute phase of PE, syncope is currently included in only two of 20 available risk assessment models, 7 underlining the fact that its prognostic role remains controversial. The aim of this systematic review and meta-analysis was to investigate the association between syncope and (i) baseline haemodynamic parameters of PE severity and (ii) short-term adverse outcomes.
Methods Literature search and study selection
We conducted a systematic literature search for relevant publications in PubMed and EMBASE from inception to 24 May 2017 (strategy available as Supplementary material online). We additionally performed a manual search of potentially eligible studies within references of the included studies, international guidelines, studies of prognostic scores, and grey literature.
We included studies which met all of the following criteria: (i) objectively confirmed or (for the purpose of sensitivity analysis) 'very likely' diagnosis of acute PE; the latter included, for example, a positive leg vein compression ultrasound in patients with high pre-test PE probability; (ii) reported and documented syncope at the time of acute PE diagnosis; and (iii) evaluation of at least one of the primary outcomes of interest. The authors of publications with missing data were contacted via email.
Search results were screened by two reviewers for relevance of titles and abstracts; we performed this process in duplicate. Second selection of full-texts and data extraction was performed independently by two reviewers. Disagreements were resolved through discussion. We used the PRISMA statement and the MOOSE guidelines as a basis for reporting the results. 8, 9 
Study objectives
We sought to assess the following variables according to the presence or absence of syncope in patients with acute PE at presentation: (i) prevalence of (persistent) systemic hypotension or haemodynamic instability; (ii) proportion of patients with right ventricular (RV) dysfunction on imaging tests; (iii) the incremental risk of death or PE-related complications during hospital stay or within 30 days of the index PE event. We also performed a sub-analysis of the results of studies focusing on patients who were reportedly haemodynamically stable.
Definitions of baseline variables and outcomes
Haemodynamic instability at clinical presentation was assumed to be present when the studies reported: (i) systolic blood pressure persistently (in most cases, over 15 min or longer) below 100 or 90 mmHg, particularly when there was need for vasopressors or frank shock with end-organ hypoperfusion or (ii) PE defined as 'high-risk'. 10 The presence of RV dysfunction at presentation was defined on the basis of echocardiography or computed tomographic pulmonary angiography (CTPA) parameters. Since the definition of RV dysfunction varied over time, we accepted the presence of at least one of the following criteria: (i) dilatation of the right ventricle (diastolic diameter > _30 mm in the parasternal short-axis view) or a right/left ventricular (RV/LV) enddiastolic diameter ratio >0.9 (or >1.0) in the four-chamber view; (ii) hypokinesis of the RV free wall; (iii) abnormal motion of the interventricular septum; (iv) tricuspid valve regurgitation velocity > _2.7 or 2.8 m/s; or (v) CTPA-assessed RV/LV diameter ratio >0.9 (or >1.0). 6 Short-term mortality was considered as death occurring during hospitalization or within 30 days of PE diagnosis (the latter information was preferred if both sets of data reported). Early adverse outcomes included cardiorespiratory collapse (need for mechanical ventilation, cardiopulmonary resuscitation, or catecholamine administration) and/or recurrent venous thromboembolism within 30 days of PE diagnosis.
Two authors independently assessed the quality of studies focusing on clinical outcomes in accordance with the Newcastle-Ottawa Scale for cohort studies. 11 In the absence of validated tools allowing for a dichotomization of the results and of clear usage rules for this scale, 12 we adopted an arbitrary threshold based on the median value for subgroup analysis.
Statistical analysis
To assess the association for syncope and study outcomes, we calculated the pooled ORs and 95% confidence intervals (CIs), applying a randomeffect model (method of DerSimonian & Laird, estimate of heterogeneity taken from the Mantel-Haenszel model). 13 We assessed statistic heterogeneity of exposure effects by calculating the I 2 statistic, which depicts the variance of results from study to study beyond (or rather than) chance. Heterogeneity was defined as low in when I 2 < 25%, moderate when I 2 = 25-75%, and high when I 2 > 75%. 14 For the calculation of the weighed pooled rates (95% CI) and absolute risk differences (95% CI), we applied the random-effect model. We evaluated differences across subgroups under the null hypothesis of no differences [v 2 distribution with S (number of subgroups) minus one degrees of freedom]. In case of studies reporting only the measure of association and the authors not willing or able to provide data for subgroups, missing data were retrieved either by resolving standard quadratic equation or by adopting the generic inverse variance method. The presence of publication bias was evaluated by visually inspecting funnel plots. We performed subgroup analyses in order to investigate a differential effect of syncope on all-cause vs. PE-related 30-day mortality and whether the observed pooled risks were different among subgroups categorized by study design, setting, and quality. 
Results
Literature search and study selection
The initial literature search identified 1481 records in EMBASE and 458 in PubMed (N = 1664 studies after duplicate removing; Supplementary material online, Figure S1 ). After first selection based on titles and abstracts, we excluded 1576 studies and assessed 88 in full-text. A total of five studies, [15] [16] [17] [18] [19] Table S2 ). The descriptions of all the study outcomes (haemodynamic parameters, short-term death, 30-day composite outcome) are summarized in Supplementary material online, Table S3 . A total of 22 cohort studies evaluating clinical outcomes were assessed with the Newcastle-Ottawa Scale: the median score was six (Supplementary material online, Table S4 ).
Association of syncope with clinical severity of acute pulmonary embolism
A total of 10 studies provided data of the patients' haemodynamic status at diagnosis. 4, 24, [28] [29] [30] 32, 34, 36, 37, 41, 42 The pooled OR for concomitant systemic hypotension or haemodynamic instability at presentation was 3.50 (95% CI 2.67-4.58) in patients with syncope upon or following the onset of symptoms ( Figure 1 ). This corresponded to a prevalence of 16.2% (95% CI 7.8-26.8%) in patients with, compared with 5.9% (3.0-8.8%; I 2 = 0%) in patients without syncope for an absolute difference of þ11% (þ1% to þ20%). Echocardiography was performed for the assessment of RV dysfunction in 14 studies, 15, 16, 18, 19, 21, 22, 24, 26, 29, 31, 34, 37, 38, 41 with a delay between the time of PE diagnosis and assessment ranging from 30 min to 5 days (<48 h in eight out of nine studies in which precise timing was specified; Supplementary material online, Table S3 ). Supplementary material online, Figure S2 .
Association of syncope with early adverse outcomes in unselected patients with acute pulmonary embolism A total of 20 studies evaluated the short-term (either in-hospital or 30-day) risk of all-cause death. 2, 3, 15, 16, 18, 19, 21, 24, 25, [27] [28] [29] [30] 32, 34, 35, 37, [39] [40] [41] Syncope was associated with an increased risk of short-term death (OR 1.73, 95% CI 1.22-2.47; I 2 = 63.2%; Figure 2 Figure 3 ). Weighed pooled rates (95% CI) of inhospital death were 11.2% (5.9-16.5%) in patients with and 7.0% (4.5-9.5%) in patients without syncope; for 30-day mortality, the rates were 7.4% (3.4-12.5%) and 5.2% (3.9-6.4%), respectively.
A total of seven studies reported data on PE-related 30-day adverse outcomes. 15, [17] [18] [19] 21, 23, 41 In five studies, the composite outcome included PE-related death, haemodynamic collapse, and recurrent PE [18] [19] [20] 23 (or venous thromboembolism), 17 whereas in two studies recurrent PE was not included. 21, 41 Patients with syncope had a twofold increased risk of developing 30-day PE-related complications (OR 2.00, 95% CI 1.11-3.60; I 2 = 61.5%; Figure 4 ). Weighed pooled rates (95% CI) were 12.8% (7.5-18.9%) in patients with and 7.2% (4.8-9.6%) in patients without syncope.
Prognostic impact of syncope in haemodynamically stable patients
We performed a separate analysis for the association between syncope and initial RV dysfunction at clinical presentation, short-term mortality, and 30-day adverse outcomes, including only studies in haemodynamically stable (normotensive) patients at presentation ( Figures 2-4 ).
In particular, we calculated an OR (95% CI) of 1.87 (1.42-2.45) for the association with RV dysfunction compared with 2.87 (1.57-5.26) in studies with a mixed population; Supplementary material online, Figure S2 ). Absolute risk difference (95% CI) was þ23% (þ14% to þ32%) in studies including mixed populations and þ12% (þ6% to þ18%) in studies including haemodynamically stable patients (test for subgroup differences: P = 0.05).
The OR for short-term death in haemodynamically stable patients was 1.12 (0.61-2.05): the absolute risk difference (95% CI) was þ6% (þ1% to þ10%) in studies including mixed populations, but it was -1% (-2% to þ1%) in studies including haemodynamically stable patients (P = 0.01). The OR for 30-day PE-related complications was 1.62 (0.97-2.70): the absolute risk difference (95% CI) was þ10% (-6% to þ25%) in studies including mixed populations and þ3% (-2% to þ8%) in studies including haemodynamically stable patients (P = 0.42).
Sensitivity analyses
The association between syncope and early mortality appeared more pronounced in studies characterized by a lower score at formal quality assessment [OR 3.00 (95% CI 1.68-5.35), absolute risk difference þ11% (þ4% to þ18%)] than in studies with a higher score [OR 1.05 (95% CI 0.82-1.36), absolute risk difference 0% (-1% to þ0%)] for a P-value for subgroup differences = 0.001; Table 2 ). An interaction was observed by analysing single components of study quality, in particular when comparing studies with a retrospective [OR 2.50 (1.48-4.23), absolute risk difference þ9% (þ2% to þ15%)] vs. prospective [OR 1.18 (0.80-2.47), absolute risk difference 0% (-2% to þ2%)] design (P = 0.009). It did not reach statistical significance for the other items ( Table 2) .
The association between syncope and all-cause death (OR 1.84, 95% CI 1.22-2.78) appeared stronger than for PE-related death [1.23 (0.67-2.26); P-value for subgroup differences = 0.07; Table 2 ]. 
Publication bias

Discussion
The results of this meta-analysis indicate that patients with acute PE who presented with syncope frequently had signs of haemodynamic instability and/or RV dysfunction, and they appeared to be at an increased risk of an early adverse outcome. However, the association between syncope and patient outcomes was attenuated, and in fact no longer significant, in studies focusing on normotensive patients with acute PE, when compared with studies on mixed populations. These differences suggest that haemodynamic instability (rather than syncope itself) may represent the main predictor of early outcome. These findings, along with the observations of our sensitivity analyses in which the role of syncope was mostly supported by studies with a lower score at formal quality assessment and by retrospective studies, question the notion that syncope may provide additional information for risk stratification when compared with patient's haemodynamic status at presentation. There are at least two possible explanations for our results, which may in fact complement each other. The first is based on the pathophysiology of syncope in the setting of acute PE. The notion that reduced cardiac output may explain syncope 'only' in 29 only data of normotensive patients were used. In one multicentre study, 20 only data from one centre were still available. PE, pulmonary embolism; RV, right ventricular. 22, 30 In this meta-analysis, syncope was clearly associated with echocardiographic signs of RV dysfunction at presentation (also in haemodynamically stable patients) and with haemodynamic instability. Our results further show that, for all the short-term outcomes tested, the predictive value of syncope appeared lower in studies restricted to normotensive patients. In particular, the absolute risk difference (95% CI) for all-cause death was -1% (-2% to þ1%) in studies restricted to normotensive patients, but it was þ6% (þ1% to þ10%) in studies including unselected patients.
In normotensive patients, syncope may be better explained by mechanisms not related to the burden of pulmonary vascular obstruction and right heart failure, such as a vasovagal reflex, transient arrhythmias, or seizures. 24, 32 To further support the concept of a confounded association between syncope and adverse outcomes, one should note that 11 studies investigated its predictive role, 2, 3, 18, 20, 25, 27, 33, 36, 37, 41 but only three confirmed a significant association at multivariable regression analysis. 21, 27, 39 Importantly, we also found in our sensitivity analyses that the (presumed) impact of syncope on PE-related mortality was smaller than that on all-cause death, suggesting that syncope may have been not only a 'surrogate' for serious comorbidity, but simply occurring more often in older patients. 24, 30 The second explanation is a methodological one: it suggests that the unadjusted association between syncope and adverse early outcomes found in our meta-analysis may be biased, since it was predominantly found in studies characterized by a lower score at formal quality assessment and in retrospective studies, while publication bias cannot be excluded. Although not reaching statistical significance, the association appeared overall weaker also when single quality items related to the study characteristics were considered ( Table 2) .
Large prospective studies with clear definitions of syncope (and data on whether patients had had previous syncopal episodes), outcomes, handling of missing values, and clinical as well as echocardiographic assessment protocols are lacking in the literature. With or without acute PE, syncope remains difficult to define, usually being reported by relatives, bystanders, or paramedics. 44 It is therefore reasonable to assume that ambiguities in definition and reporting may translate into imprecise estimates of its prevalence (an overall 17% overall in the studies included in this work) as well as associated risk among patients with acute PE. A recent major cohort study reported that approximately 17% of patients with a first episode of syncope not due to other causes were diagnosed with acute PE, while also found that as many as 25% of these patients had no associated clinical manifestations, such as tachycardia, for example, indicating severe PE. 5 One of the advantages of performing a meta-analysis including a large number of studies (in this work, N = 28) and patients (N = 21 806) is that such an approach allows us to provide robust risk estimates, which one would not achieve in single studies with smaller sample sizes. Moreover, we observed moderate statistical heterogeneity for the risk of developing early adverse events, which Iqbal (2017) Castelli (2003) Hobohm (2016) Casazza (2012) Altinsoy (2016) Lazaro Mendes (2016) Keller (2016) Kukla (2015) Barrios (2016) Jimenez (2014) Kumasaka ( Keller (2016) Castelli (2003) Kukla (2015) Casazza ( Iqbal (2017) Barrios (2016) Casazza (2012) Subtotal (I-squared = 77.0%, p = 0.000) Absolute risk difference (95% confidence interval) was þ7% (0% to þ14%) in studies including mixed populations and -3% (-4% to -1%) in studies including haemodynamically stable patients (test for subgroup differences: P = 0.01). (B) Absolute risk difference (95% confidence interval) was þ5% (-1% to þ10%) in studies including mixed populations and -1% (-2% to -1%) in studies including haemodynamically stable patients (test for subgroup differences: P = 0.09). 45 
Conclusion
In conclusion, the results of our meta-analysis suggest that, in patients with acute PE, the presence of syncope at the time of presentation was associated with a higher prevalence of haemodynamic instability and echocardiographic signs of RV dysfunction, and with an elevated risk for PE-related adverse outcomes within 30 days of diagnosis. Based on our results, we postulate that the patients' haemodynamic status may represent a confounder for the non-causal association between syncope and clinical outcomes. Adequately sized prospective cohort studies with (i) clear definitions of baseline and outcome variables including syncope itself, (ii) a low risk of bias, and (iii) complete systematic follow-up over at least 30 days, must become available before 'novel' risk factors can be established and currently used risk stratification criteria modified. Ultimately, it is only prospective management trials, which can answer the question whether the presence of syncope at diagnosis independently justifies any deviation from risk-adjusted management strategies as these are recommended in current European and other international guidelines.
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